13.53
0.32 (2.42%)
| Previous Close | 13.21 |
| Volume | 2,139,450 |
| Price / Sales | 11.15 |
| Price / Book | 2.13 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.49 |
| Total Debt/Equity (MRQ) | 3.25% |
| Current Ratio (MRQ) | 21.47 |
| Operating Cash Flow (TTM) | -39.28 M |
| Levered Free Cash Flow (TTM) | -26.34 M |
| Return on Assets (TTM) | -22.95% |
| Return on Equity (TTM) | -33.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Contineum Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.82% |
| % Held by Institutions | 79.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Johnson & Johnson | 30 Jun 2026 | 1,979,173 |
| Balyasny Asset Management L.P. | 30 Jun 2026 | 1,522,793 |
| Longaeva Partners L.P. | 30 Jun 2026 | 812,757 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| STENGONE CARMINE N. | - | 15.94 | -2,500 | -39,850 |
| Aggregate Net Quantity | -2,500 | |||
| Aggregate Net Value ($) | -39,850 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 15.94 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| STENGONE CARMINE N. | Officer | 08 Sep 2026 | Automatic sell (-) | 2,500 | 15.94 | 39,850 |
| STENGONE CARMINE N. | Officer | 08 Sep 2026 | Option execute | 2,500 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |